{
    "nct_id": "NCT00285077",
    "title": "Long-Term Safety Extension of Phase II Study EFC5286 of SR57667B in Patients With Mild-to-Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2008-12-22",
    "description_brief": "The primary objective is to assess the long term safety/tolerability of 4 mg/day of SR57667B in comparison to placebo in patients with mild-to-moderate Alzheimer's Disease (AD).\n\nA secondary objective is to describe the long term progression of Alzheimer's symptoms in patients treated by 4 mg/day of SR57667B.",
    "description_detailed": "Multinational, multicenter, randomized, parallel-group, double-blind, phase II study",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "SR57667B (paliroden)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests SR57667B (also called paliroden) as an oral drug given 4 mg/day versus placebo to patients with mild-to-moderate Alzheimer disease; the stated objectives are safety/tolerability and to describe progression of Alzheimer symptoms, implying an intent to affect disease course rather than only treat behavioral symptoms. \ue200cite\ue202turn2search0\ue202turn2search1\ue201",
        "Act: SR57667B is identified in trial registries and drug databases as paliroden, an orally active, non-peptidic small molecule with reported neurotrophic/neuroprotective properties (it was developed by Sanofi and studied in phase II trials for AD and PD). This makes it a small-molecule therapeutic aimed at neurobiological mechanisms rather than a biologic (antibody/vaccine) or a symptomatic neuropsychiatric agent. \ue200cite\ue202turn2search0\ue202turn2search8\ue202turn2search5\ue201",
        "Reflect: Given paliroden's small-molecule chemistry and its described neurotrophic / neuroprotective mechanism (not a biologic), the correct category is \"disease-targeted small molecule.\" Notes: some sources discuss related compounds (e.g., xaliproden) acting via 5-HT1A and pro-neurotrophic pathways\u2014this supports paliroden being a small-molecule neurotrophic agent rather than a cognitive-only symptomatic enhancer. Development was later discontinued for insufficient efficacy, but that does not change the original trial's category. \ue200cite\ue202turn1search3\ue202turn1search6\ue202turn2search8\ue201"
    ],
    "agent_type": "E) Neurogenesis",
    "explanation_agent": [
        "Reason: The trial is a long-term safety extension testing SR57667B (paliroden) 4 mg/day versus placebo in mild\u2011to\u2011moderate Alzheimer disease with objectives including describing progression of AD symptoms \u2014 implying a disease\u2011targeting, potentially neurobiological effect rather than only symptomatic treatment. \ue200cite\ue202turn3search0\ue201",
        "Act: SR57667B (paliroden) is described in drug databases and the literature as an orally active, non\u2011peptidic neurotrophic / neuroprotective small molecule that stimulates endogenous neurotrophin synthesis and has been reported to affect adult brain neurogenesis; related compounds (e.g., xaliproden) act via pro\u2011neurotrophic signaling (5\u2011HT1A \u2192 MAPK/Akt pathways), supporting classification as a neurotrophic/neurogenesis\u2011oriented small molecule. \ue200cite\ue202turn1search1\ue202turn2search2\ue202turn1search0\ue201",
        "Reflect: Because the drug's reported mechanism emphasizes neurotrophic effects and promotion of neurogenesis (rather than targeting amyloid, tau, ApoE/lipids, inflammation, vasculature, etc.), the most specific CADRO match is E) Neurogenesis. Development history (discontinued for insufficient efficacy) does not change the mechanism\u2011based categorization. \ue200cite\ue202turn1search4\ue201",
        "Web search results (key sources used):",
        "- Clinical trial entry describing the long\u2011term safety extension of SR57667B (paliroden) in mild\u2011to\u2011moderate AD. \ue200cite\ue202turn3search0\ue201",
        "- DrugBank entry summarizing SR57667B (paliroden) as an orally active neurotrophic/non\u2011peptidic compound. \ue200cite\ue202turn1search1\ue201",
        "- Curr Alzheimer Res review/article noting effects of paliroden and xaliproden on adult brain neurogenesis. \ue200cite\ue202turn2search2\ue202turn2search0\ue201",
        "- PubMed reports on xaliproden (a related compound) demonstrating neurotrophic effects mediated by 5\u2011HT1A \u2192 MAPK and Akt signaling, supporting the neurotrophic/neurogenesis classification. \ue200cite\ue202turn1search0\ue201",
        "- Development status summary noting paliroden\u2019s development was later discontinued for insufficient efficacy (context only). \ue200cite\ue202turn1search4\ue201"
    ]
}